Helix Acquisition Corp. II (HLXB) to Combine with BridgeBio Oncology in $360M Deal
Helix II (NASDAQ:HLXB) has entered into a definitive agreement to combine with cancer drug developer BridgeBio at an enterprise value of $360 million. San Francisco-based BridgeBio is developing a trio of potential treatments specifically targeting the KRAS mutation in some lung, breast, pancreatic, and colon cancers. The combined company is expected to trade on the
Read More
To access this post, you must purchase 1 - User: Monthly Plan.